Se încarcă compania
BioStem Technologies, Inc.
BSEM · Nasdaq · ·
3,88 USD-5,0 %închidere 29 sept.
- 1M
- +10,7 %
BSEM · Nasdaq · ·
3,88 USD-5,0 %închidere 29 sept.
Din raportul 8-K al companiei.
Pentru BioStem Technologies, Inc. nu este disponibilă nicio transcriere a unei conferințe de rezultate.
“The recent completion of our uplisting to Nasdaq was a monumental capital markets milestone for BioStem. This achievement enhances our visibility, broadens our access to institutional capital, and reflects the significant work our team has done to strengthen the foundation of the Company,”
Citat cuvânt cu cuvânt din comunicat și afișat doar atunci când raportarea îl atribuie unei persoane numite.
Comunicatele apar după închidere sau înainte de deschidere, deci mișcarea este cea a ședinței următoare.
Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion product lines. Join BioStem’s Distribution List & Social Media: To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .
Descrierea proprie a companiei, așa cum apare la finalul comunicatului.
Citatul și descrierea companiei provin din raportul 8-K la punctul 2.02 depus de BioStem Technologies, Inc. pe 12 august 2026; tabelul este construit din rapoartele trimestriale. Citește comunicatul pe EDGAR Prețurile sunt ajustate pentru splituri și dividende.